Trial Outcomes & Findings for The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia (NCT NCT01146457)
NCT ID: NCT01146457
Last Updated: 2017-04-25
Results Overview
Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.
TERMINATED
NA
83 participants
Participants were followed for the duration of delivery, an average of 7 hours
2017-04-25
Participant Flow
Participant milestones
| Measure |
Placebo
Saline: Saline Control
|
Morphine 25
Morphine 25 micrograms: Active dosage
|
Morphine 50
Morphine 50 micrograms: Active dosage
|
Morphine 75
Morphine 75 micrograms: Active dosage
|
Morphine 100
Morphine 100 micrograms: Active dosage
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
19
|
17
|
21
|
13
|
13
|
|
Overall Study
COMPLETED
|
19
|
17
|
20
|
13
|
13
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
1
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia
Baseline characteristics by cohort
| Measure |
Placebo
n=19 Participants
Saline control
|
Morphine 25
n=17 Participants
Morphine 25 micrograms
|
Morphine 50
n=21 Participants
Morphine 50 micrograms
|
Hine 75
n=13 Participants
Morphine 75 micrograms
|
Morphine 100
n=13 Participants
Morphine 100 micrograms
|
Total
n=83 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
34.3 Years
STANDARD_DEVIATION 5.3 • n=5 Participants
|
31.5 Years
STANDARD_DEVIATION 5.3 • n=7 Participants
|
31.3 Years
STANDARD_DEVIATION 6.6 • n=5 Participants
|
32.5 Years
STANDARD_DEVIATION 5.5 • n=4 Participants
|
32.4 Years
STANDARD_DEVIATION 5.7 • n=21 Participants
|
32.3 Years
STANDARD_DEVIATION 5.7 • n=8 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
13 Participants
n=21 Participants
|
83 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Participants were followed for the duration of delivery, an average of 7 hoursRate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.
Outcome measures
| Measure |
Control
n=19 Participants
Saline Control
|
Morphine 25
n=17 Participants
Morphine 25 micrograms
|
Morphine 50
n=21 Participants
Morphine 50 micrograms
|
Morphine 75
n=13 Participants
Morphine 75 micrograms
|
Morphine 100
n=13 Participants
Morphine 100 micrograms
|
|---|---|---|---|---|---|
|
Rate of Breakthrough Pain
|
0.25 episodes of breakthrough pain per hour
Standard Deviation 0.29
|
0.28 episodes of breakthrough pain per hour
Standard Deviation 0.35
|
0.25 episodes of breakthrough pain per hour
Standard Deviation 0.25
|
0.23 episodes of breakthrough pain per hour
Standard Deviation 0.26
|
0.17 episodes of breakthrough pain per hour
Standard Deviation 0.21
|
Adverse Events
Placebo
Morphine 25
Morphine 50
Morphine 75
Morphine 100
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place